Dr. Mitul D. Gandhi, MD

Dr. Gandhi practices at Virginia Cancer Specialists in Gainesville, Virginia.

Dr. Gandhi's NPI, 1639379308, was assigned on July 20, 2007. Dr. Gandhi graduated from Rutgers Robert Wood Johnson Medical School in 2007. Dr. Gandhi holds Virginia license 0101257153.

Dr. Gandhi's primary practice is Virginia Cancer Specialists, at 7901 Lake Manassas Dr, Gainesville, VA 20155 in Prince William County. The practice phone is (703) 280-5390.

Dr. Gandhi's primary practice is Virginia Cancer Specialists in Gainesville, Virginia. Dr. Gandhi is also affiliated with Reston Hospital Center. The medical group on file is Virginia Cancer Specialists. Dmand AI also links Dr. Gandhi to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gandhi practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Gandhi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Gandhi is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Gandhi's licenses on file in 4 states: Virginia, Illinois, New Jersey and Michigan.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Gandhi treats.

CMS data shows 57,386 Medicare services from Dr. Gandhi across 63 procedure codes in 2024, for 598 Medicare patients. Medicare paid $1,217,036 for them.

CMS counts 598 Medicare patients who saw Dr. Gandhi in 2024. The largest group is 75 to 84, with 281 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gandhi's median patient age at 66, with 55% women.

In 2024, Dr. Gandhi wrote 876 Medicare Part D claims for 160 patients. 80% of them were for generic drugs. CMS names the drug for 720 of them, across 21 drugs with 11 or more claims each, at $2,722,796 in total drug cost. In 2023, CMS named 666 claims across 23 drugs.

Dr. Gandhi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gandhi as offering telehealth.

Dmand AI links 27 papers to Dr. Gandhi, published from 2010 to 2025. 2014 was the busiest year, with 5. The most frequent topics are Hodgkin Disease, Antineoplastic Combined Chemotherapy Protocols and Benzamides. Dr. Gandhi has published most often in Blood. Dr. Gandhi's most frequent co-authors are Ian Winchester Flinn, MD, Moshe Yair Levy, MD and John McEvoy Burke, MD.

Dmand AI links Dr. Gandhi to 10 clinical trials, 4 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, B-Cell and Breast Neoplasms. Loxo Oncology, Inc. sponsors the most, 3. Open Payments lists research payments to Dr. Gandhi that name 3 trials.

CMS Open Payments shows 107 general payments to Dr. Gandhi from 38 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. Pfizer Inc. paid the most, $2,119. It also lists 12 research payments totaling $14,280 from 2020 to 2025, naming 3 clinical trials.

Dr. Gandhi graduated from Rutgers Robert Wood Johnson Medical School in 2007.

Dr. Gandhi is in network with 20 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 13. Check the plan with the practice before a visit.